ABUS earnings: real EPS beat/miss history, analyst consensus Buy, P/E 5.19. Updated 2026-07-23.
Arbutus Biopharma (ABUS) Research Hub
Arbutus Biopharma (ABUS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 5.12 USD (-0.97%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 5.19, market cap 0.86B. This hub links to the full technical, earnings and options research available for ABUS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 5.12 USD (-0.97%) |
| 52-week range | 4.26 USD – 5.45 USD |
| Trend regime | Range |
| 14-day RSI | 72.9 (Overbought) |
| Trailing P/E | 5.19 |
| Market cap | 0.86B |
| Dividend yield | 0.00% |
Available research for ABUS
Covered Call on ABUS: how it works, illustrative setup around the real 5.12 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ABUS: how it works, illustrative setup around the real 5.12 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ABUS: how it works, illustrative setup around the real 5.12 USD price, max profit/loss, breakeven and when to use it. Educational.
ABUS technical analysis: range, last 5.12 USD, RSI 72.9, 52w range 4.26 USD–5.45 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ABUS in?
Arbutus Biopharma (ABUS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ABUS in an uptrend or downtrend?
As of 2026-09-11, ABUS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ABUS's trailing P/E ratio?
ABUS's trailing P/E is 5.19, with a market cap of 0.86B. See the earnings research page for full valuation detail.